Drug Testing Methodology Clause Samples
Drug Testing Methodology a. The testing or processing phase shall consist of:
(i) Initial screening test;
(ii) Confirmation test-if the initial screen testing is positive.
b. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as “confirmation pending.” Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the MRO.
c. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test.
d. The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse, including heroin, amphetamines and barbiturates. Personnel utilized for testing will be qualified to collect urine samples, or adequately trained in collection procedures.
e. Concentrations of a drug at or about the following levels shall be considered a positive test result when using the initial immunoassay drug screening test:
(i) Initial Test Standards. The initial test shall use an immunoassay which meets the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used when screening specimens to determine whether negative or positive for these classes of drugs: SKBL Analyte Initial Test Level (ng/ml) Marijuana 50 ng/ml Cocaine 300 ng/ml Opiates 2000 ng/ml Phencyclidine 25 ng/ml Amphetamine 1000 ng/ml Some specimens may be subjected to initial testing by methods other than immunoassays, where the latter are unavailable for detection of specific drugs of special concern.
(ii) Confirmatory Test Standards. All specimens identified as positive on the initial screening test shall be confirmed using gas chromatography/mass spectrometry (GC/MS) techniques and by quantitative analysis at the cutoff levels listed below: SKBL Analyte Initial Test Level (ng/ml)_ Marijuana 15 ng/ml Cocaine 150 ng/ml Opiates: Morphine 2000 ng/ml Codeine 2000 ng/ml Phencyclidine 5 ng/ml Amphetamine 500 ng/ml
Drug Testing Methodology. 1. The testing or processing phase shall consist of a two-step procedure.
a. Initial screening test.
Drug Testing Methodology. 1. The testing or processing phase shall consist of a two- step procedure:
a. initial screening test
b. confirmation test
2. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as "confirmation pending." Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the M.R.O.
3. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test.
4. The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse including heroin, amphetamines and barbiturates. Personnel utilized for testing will be qualified to collect urine samples, or adequately trained in collection procedures.
5. Concentrations of a drug at or about the following levels shall be considered a positive test result when using the initial immunoassay drug screening test: Initial Test Level (ng/ ml) Marijuana metabolite 100 Cocaine metabolite 300 Opiate metabolite 300* Phencyclidine 25 Amphetamines 1000 Barbiturates 300 *25ng/ml if immunoassay-specific for free morphine. Concentrations of a drug at or above the following levels shall be considered a positive test result when performing a confirmatory CG/MS test on a urine specimen that tested positive using a technologically different test than the initial screening method: Confirmatory Test Level Marijuana metabolite 15* Cocaine metabolite 150** Opiates: Morphine 300+ Codeine 300+ Phencyclidine ▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ 500 Methamphetamine 500 * Delta-9-tetrahydrocannabinol-9-carboxylic acid ** Benzoylecgonine + 25ng/ ml if immunoassay-specific for free morphine Barbiturates 300
6. The laboratory selected to conduct the analysis shall be experienced and capable of quality control, documentation, chain-of-custody, technical expertise and demonstrated proficiency in urinalysis.
7. Employees having negative drug test results shall receive a memorandum stating that no illegal drugs were found. A copy of the letter will be placed in the Employee's personnel file upon the Employee's request.
8. Any employee who interferes with the testing process or breaches the confidentiality of test results shall be subject to discipline.
Drug Testing Methodology. 1. The testing or processing phase shall consist of a two-step procedure:
a. Initial screening test, and
b. Confirmation test.
2. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as "confirmation pending." Notification of test results to the Deputy Chief shall be held until the confirmation test results are obtained.
3. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test and shall be performed using gas chromatography/mass spectrometry analysis.
4. The drug screening tests selected shall be capable of identifying marijuana, cocaine, and every major drug of abuse including heroin, amphetamine and barbiturates.
5. Concentrations of a drug at or above the following levels shall be considered a positive test result when using the initial immunoassay drug screening test: Initial Test Level (ng/ml) Marijuana metabolite 100 Cocaine metabolite 300 Opiate metabolite 2,000 Phencyclidine 25 Amphetamines 1,000 Concentrations of a drug at or above the following levels shall be considered a positive test result when performing a confirmation GC/MS test on a urine specimen that tested positive using a technologically different initial screening method: Confirmatory Test Level (ng/ml) Marijuana metabolite ................................................ 15 (1) Cocaine metabolite .................................................... 150 (2) Opiates: (1) Delta-9-tetrahydrocannabinol-9-carboxylic acid
Drug Testing Methodology. 1. The testing or processing phase shall consist of a two-step procedure:
a. initial screening test
b. confirmation test
2. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as "confirmation pending." Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the M.R.O.
3. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test.
4. The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse including heroin, amphetamines and barbiturates. Personnel utilized for testing will be certified as qualified to collect urine sample or adequately trained in collection procedures.
5. Concentrations of a drug at or about the following levels shall be considered a positive test result when using the initial immunoassay drug screening test: Marijuana metabolite . . . . . . . . . . 100 Cocaine metabolite . . . . . . . . . . . 300 Opiate metabolite. . . . . . . . . . . . 300* Phencyclidine. . . . . . . . . . . . . . 25 Amphetamines . . . . . . . . . . . . . . 1000 Barbiturates . . . . . . . . . . . . . . 300 *25ng/ml if immunoassay-specific for free morphine. Concentrations of a drug at or above the following levels shall be considered a positive test result when performing a confirmatory CG/MS test on a urine specimen that tested positive using a technologically different test than the initial screening method: Confirmatory Test Level Marijuana metabolite . . . . . . . . . . 15* Cocaine metabolite . . . . . . . . . . . 150** Opiates: Morphine. . . . . . . . . . . . . . 300+ Codeine . . . . . . . . . . . . . . 300+ Phencyclidine. . . . . . . . . . . . . . 25 Amphetamines Amphetamine . . . . . . . . . . . . 500 Methamphetamine . . . . . . . . . . 500 * Delta-9-tetrahydrocannabinol-9-carboxylic acid ** Benzoylecgonine + 25ng/ml if immunoassay-specific for free morphine
Drug Testing Methodology. 1148 a) The testing or processing phase shall consist of a two-step procedure: 1149 i. Initial screening test as defined in 34.4.5(b). (All employees shall receive 1150 the same initial screening test.) 1151 ii. Confirmation test (GCMS) 1152 b) The urine sample is first tested using the initial drug screening procedure. An 1153 initial positive test result will not be considered conclusive; rather, it will be 1154 classified as “confirmation pending.” Notification of test results to the Chief 1155 shall be held until the confirmation test results are obtained.
Drug Testing Methodology. 24 1. The testing or processing phase shall consist of a two step procedure.
25 A. Initial screening test.
26 B. Confirmation test.
27 2. The urine sample is first tested using the initial drug screening procedure. 28 The laboratory will not release a positive screening result to the City of 29 Mequon until it has been confirmed by alternate more specific methods 30 (GC/MS).
1 3. A specimen testing positive will undergo an additional confirmatory test.
Drug Testing Methodology. 1. The testing or processing shall consist of a two-step procedure: (1) initial screening test; and (2) confirmation test. The urine sample shall be tested first using an initial drug screening procedure. Notification to a departmental designee of a positive test shall not be made until a confirmation test is conducted.
2. All urine drug testing performed under this policy shall be performed by a professionally qualified laboratory meeting standards defined by local, state or federal authorities. A ten (10) panel drug test shall be used. All urine drug testing performed under this policy shall be performed by a licensed professional laboratory, meeting standards defined by local, state, or federal authorities.
3. Prior to testing, the employee will be provided by personnel at the testing location with a “Consent to a Urinalysis Test and Authorization for Release of Medical Information”. The form will specify, inter alia, that its use will be limited to internal, administrative purposes only, and that it will not be used in connection with any criminal investigation or prosecution of the employee. If the employee will fail or refuse to execute the form, he/she will not be tested. Such failure or refusal, however, will be deemed to be a failure or refusal to submit to a duly authorized drug test and will constitute a disobedience to an order. This will subject the employee failing or refusing to disciplinary action, which could include dismissal.
4. Specimen collection will occur in a medical setting and without direct observation. The procedures will not be designed to knowingly demean, embarrass or cause physical discomfort to the employee being tested. A directly observed collection will be mandated if:
a. Materials were observed being brought to the collection site or the employee’s conduct clearly indicates an attempt to tamper with a specimen; or
b. the temperature on the original specimen was out of range; or
c. the original specimen appeared to have been tampered with; or
d. the laboratory reports that a specimen is invalid, and the laboratory’s Medical Director advises there is not an adequate medical explanation for the result. Samples of negative specimens will not be kept. A positive tested specimen will be retained by the medical provider for a period of one year for use by the employee, in the event he/she should elect to challenge a positive test result by means of independent testing of the specimen at the employee’s expense. If that test sho...
Drug Testing Methodology. 1. The testing or processing phase shall consist of a two-step procedure:
a. initial screening test
b. confirmation test
2. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as "confirmation pending". Notification of test results to the Director shall be held until the confirmation test results are obtained and verified by the M.R.O.
3. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test.
4. The initial drug screening tests selected shall be capable of identifying marijuana, cocaine, and methamphetamine. Personnel utilized for testing will be certified as qualified to collect urine samples or adequately trained in collection procedures. Concentrations of a drug at or above the following levels shall be considered a positive test result when performing a confirmatory CG/MS test on a urine specimen that tested positive using a technologically different test than the initial screening method: Marijuana metabolite 15* Cocaine metabolite 150** Opiates: Morphine 300+ Codeine 300+ Phencycline 25 Amphetamines: Amphetamine 500 Methamphetamine 500 *Delta-9-tetrahydrocannabinol-9-carboxylic acid **Benzoylecgonine + 25ng/ml if immunoassay-specific for free morphine Barbiturates 300
5. The laboratory selected to conduct the analysis shall be experienced and capable of quality control, documentation, chain-of-custody, technical expertise and demonstrated proficiency in urinalysis.
6. Employees having negative drug test results shall receive a memorandum stating that no illegal drugs were found. A copy of the letter will be placed in the employee's personnel file upon the employee's request.
7. Any employee who interferes with the testing process or breaches the confidentiality of test results shall be subject to discipline.
Drug Testing Methodology. 1. The testing or processing phase shall consist of:
a. initial screening test;
b. confirmation test -- if the initial screening test is positive.
2. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as "confirmation pending." Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the MRO.
3. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test.
4. The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse including heroin, phencyclidine, amphetamines, and barbiturates. Personnel utilized for testing will be qualified to collect urine samples, or adequately trained in collection procedures.
5. Concentrations of a drug at or about the following levels shall be considered a positive test result when using the initial immunoassay drug screening test:
6. Type of drug or metabolite, initial test and confirmation test levels shall be as provided in 49 CFR Part 40.87 (attached). These cutoff levels are subject to change by the Department of Health and Human Services as advances in technology or other considerations warrant identification of these substances at other concentrations. If these cutoff levels change in the future, the matter will be discussed with the labor associations prior to any amendment of the department’s general order.
7. The laboratory selected to conduct the analysis shall be experienced and capable of assuring quality control, documentation, chain-of-custody, technical expertise, and demonstrated proficiency in urinalysis.
8. Employees having negative drug test results shall receive a memorandum stating that no illegal drugs were found. A copy of the letter will be placed in the employee’s personnel file upon the employee’s request.
9. Any employee who interferes with the testing process or breaches the confidentiality of test results shall be subject to discipline.